APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Hepatocellular Carcinoma Drug

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Hepatocellular Carcinoma Drug Industry Growth and Trends Forecast to 2032

Report ID 173998030122 December 2025106 pages

Choose your research edition.

Industry ResearchHepatocellular Carcinoma Drug Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Hepatocellular Carcinoma Drug Industry Growth and Trends Forecast to 2032106 pages · $3,450 USDMarket StructureGlobal Hepatocellular Carcinoma Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hepatocellular Carcinoma Drug Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Hepatocellular Carcinoma Drug Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Hepatocellular Carcinoma Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Hepatocellular Carcinoma Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Hepatocellular Carcinoma Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Hepatocellular Carcinoma Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Hepatocellular Carcinoma Drug include Teva Pharmaceutical, Sun Pharmaceutical, Johnson & Johnson, Novartis, Sigma-Tau Group, Pacira, Luye Pharma, Kingond Pharm and Gilead Sciences, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Hepatocellular Carcinoma Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Hepatocellular Carcinoma Drug market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Hepatocellular Carcinoma Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Hepatocellular Carcinoma Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Hepatocellular Carcinoma Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Hepatocellular Carcinoma Drug Market by Company

Teva Pharmaceutical

Sun Pharmaceutical

Johnson & Johnson

Novartis

Sigma-Tau Group

Pacira

Luye Pharma

Kingond Pharm

Gilead Sciences

Fudan-Zhangjiang

CSPC

Hepatocellular Carcinoma Drug Segment by Type

Ablation Therapy

Brachytherapy

Chemotherapy

Hepatocellular Carcinoma Drug Segment by Application

Surgical Resection

Ablation

Liver Transplantation

Hepatocellular Carcinoma Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hepatocellular Carcinoma Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hepatocellular Carcinoma Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hepatocellular Carcinoma Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Hepatocellular Carcinoma Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Hepatocellular Carcinoma Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Ablation Therapy Table 2. Major Company of Brachytherapy Table 3. Major Company of Chemotherapy Table 4. Global Hepatocellular Carcinoma Drug Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Hepatocellular Carcinoma Drug Sales by Type (2021-2026) & (k units) Table 6. Global Hepatocellular Carcinoma Drug Sales Market Share in Volume by Type (2021-2026) Table 7. Global Hepatocellular Carcinoma Drug Sales by Type (2021-2026) & (US$ Million) Table 8. Global Hepatocellular Carcinoma Drug Sales Market Share in Value by Type (2021-2026) Table 9. Global Hepatocellular Carcinoma Drug Price by Type (2021-2026) & (US$/unit) Table 10. Global Hepatocellular Carcinoma Drug Sales by Type (2027-2032) & (k units) Table 11. Global Hepatocellular Carcinoma Drug Sales Market Share in Volume by Type (2027-2032) Table 12. Global Hepatocellular Carcinoma Drug Sales by Type (2027-2032) & (US$ Million) Table 13. Global Hepatocellular Carcinoma Drug Sales Market Share in Value by Type (2027-2032) Table 14. Global Hepatocellular Carcinoma Drug Price by Type (2027-2032) & (US$/unit) Table 15. North America Hepatocellular Carcinoma Drug Sales by Type (2021-2026) & (k units) Table 16. North America Hepatocellular Carcinoma Drug Sales by Type (2021-2026) & (US$ Million) Table 17. Europe Hepatocellular Carcinoma Drug Sales by Type (2021-2026) & (k units) Table 18. Europe Hepatocellular Carcinoma Drug Sales by Type (2021-2026) & (US$ Million) Table 19. Asia-Pacific Hepatocellular Carcinoma Drug Sales by Type (2021-2026) & (k units) Table 20. Asia-Pacific Hepatocellular Carcinoma Drug Sales by Type (2021-2026) & (US$ Million) Table 21. Latin America Hepatocellular Carcinoma Drug Sales by Type (2021-2026) & (k units) Table 22. Latin America Hepatocellular Carcinoma Drug Sales by Type (2021-2026) & (US$ Million) Table 23. Middle East and Africa Hepatocellular Carcinoma Drug Sales by Type (2021-2026) & (k units) Table 24. Middle East and Africa Hepatocellular Carcinoma Drug Sales by Type (2021-2026) & (US$ Million) Table 25. Hepatocellular Carcinoma Drug Industry Trends Table 26. Hepatocellular Carcinoma Drug Industry Drivers Table 27. Hepatocellular Carcinoma Drug Industry Opportunities and Challenges Table 28. Hepatocellular Carcinoma Drug Industry Restraints Table 29. Global Hepatocellular Carcinoma Drug Sales Revenue by Company (US$ Million) & (2021-2026) Table 30. Global Hepatocellular Carcinoma Drug Revenue Market Share by Company (2021-2026) Table 31. Global Hepatocellular Carcinoma Drug Sales by Company (2021-2026) & (k units) Table 32. Global Hepatocellular Carcinoma Drug Sales Share by Company (2021-2026) Table 33. Global Hepatocellular Carcinoma Drug Market Price by Company (2021-2026) & (US$/unit) Table 34. Global Hepatocellular Carcinoma Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 35. Global Hepatocellular Carcinoma Drug Major Company Production Sites and Headquarters Table 36. Global Hepatocellular Carcinoma Drug Company, Product Type & Application Table 37. Global Hepatocellular Carcinoma Drug Company Establishment Date Table 38. Global Company Market Concentration Ratio (CR5 and HHI) Table 39. Global Hepatocellular Carcinoma Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 40. Global Hepatocellular Carcinoma Drug Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 41. Global Hepatocellular Carcinoma Drug Sales by Region (2021-2026) & (k units) Table 42. Global Hepatocellular Carcinoma Drug Sales Market Share in Volume by Region (2021-2026) Table 43. Global Hepatocellular Carcinoma Drug Sales by Region (2021-2026) & (US$ Million) Table 44. Global Hepatocellular Carcinoma Drug Sales Market Share in Value by Region (2021-2026) Table 45. Global Hepatocellular Carcinoma Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 46. Global Hepatocellular Carcinoma Drug Sales by Region (2027-2032) & (k units) Table 47. Global Hepatocellular Carcinoma Drug Sales Market Share in Volume by Region (2027-2032) Table 48. Global Hepatocellular Carcinoma Drug Sales by Region (2027-2032) & (US$ Million) Table 49. Global Hepatocellular Carcinoma Drug Sales Market Share in Value by Region (2027-2032) Table 50. Global Hepatocellular Carcinoma Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2027-2032) Table 51. Global Hepatocellular Carcinoma Drug Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 52. Global Hepatocellular Carcinoma Drug Sales by Application (2021-2026) & (k units) Table 53. Global Hepatocellular Carcinoma Drug Sales Market Share in Volume by Application (2021-2026) Table 54. Global Hepatocellular Carcinoma Drug Sales by Application (2021-2026) & (US$ Million) Table 55. Global Hepatocellular Carcinoma Drug Sales Market Share in Value by Application (2021-2026) Table 56. Global Hepatocellular Carcinoma Drug Price by Application (2021-2026) & (US$/unit) Table 57. Global Hepatocellular Carcinoma Drug Sales by Application (2027-2032) & (k units) Table 58. Global Hepatocellular Carcinoma Drug Sales Market Share in Volume by Application (2027-2032) Table 59. Global Hepatocellular Carcinoma Drug Sales by Application (2027-2032) & (US$ Million) Table 60. Global Hepatocellular Carcinoma Drug Sales Market Share in Value by Application (2027-2032) Table 61. Global Hepatocellular Carcinoma Drug Price by Application (2027-2032) & (US$/unit) Table 62. North America Hepatocellular Carcinoma Drug Sales by Application (2021-2026) & (k units) Table 63. North America Hepatocellular Carcinoma Drug Sales by Application (2021-2026) & (US$ Million) Table 64. Europe Hepatocellular Carcinoma Drug Sales by Application (2021-2026) & (k units) Table 65. Europe Hepatocellular Carcinoma Drug Sales by Application (2021-2026) & (US$ Million) Table 66. Asia-Pacific Hepatocellular Carcinoma Drug Sales by Application (2021-2026) & (k units) Table 67. Asia-Pacific Hepatocellular Carcinoma Drug Sales by Application (2021-2026) & (US$ Million) Table 68. Latin America Hepatocellular Carcinoma Drug Sales by Application (2021-2026) & (k units) Table 69. Latin America Hepatocellular Carcinoma Drug Sales by Application (2021-2026) & (US$ Million) Table 70. Middle East and Africa Hepatocellular Carcinoma Drug Sales by Application (2021-2026) & (k units) Table 71. Middle East and Africa Hepatocellular Carcinoma Drug Sales by Application (2021-2026) & (US$ Million) Table 72. Teva Pharmaceutical Company Information Table 73. Teva Pharmaceutical Business Overview Table 74. Teva Pharmaceutical Hepatocellular Carcinoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 75. Teva Pharmaceutical Hepatocellular Carcinoma Drug Product Portfolio Table 76. Teva Pharmaceutical Recent Development Table 77. Sun Pharmaceutical Company Information Table 78. Sun Pharmaceutical Business Overview Table 79. Sun Pharmaceutical Hepatocellular Carcinoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 80. Sun Pharmaceutical Hepatocellular Carcinoma Drug Product Portfolio Table 81. Sun Pharmaceutical Recent Development Table 82. Johnson & Johnson Company Information Table 83. Johnson & Johnson Business Overview Table 84. Johnson & Johnson Hepatocellular Carcinoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 85. Johnson & Johnson Hepatocellular Carcinoma Drug Product Portfolio Table 86. Johnson & Johnson Recent Development Table 87. Novartis Company Information Table 88. Novartis Business Overview Table 89. Novartis Hepatocellular Carcinoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 90. Novartis Hepatocellular Carcinoma Drug Product Portfolio Table 91. Novartis Recent Development Table 92. Sigma-Tau Group Company Information Table 93. Sigma-Tau Group Business Overview Table 94. Sigma-Tau Group Hepatocellular Carcinoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 95. Sigma-Tau Group Hepatocellular Carcinoma Drug Product Portfolio Table 96. Sigma-Tau Group Recent Development Table 97. Pacira Company Information Table 98. Pacira Business Overview Table 99. Pacira Hepatocellular Carcinoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 100. Pacira Hepatocellular Carcinoma Drug Product Portfolio Table 101. Pacira Recent Development Table 102. Luye Pharma Company Information Table 103. Luye Pharma Business Overview Table 104. Luye Pharma Hepatocellular Carcinoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 105. Luye Pharma Hepatocellular Carcinoma Drug Product Portfolio Table 106. Luye Pharma Recent Development Table 107. Kingond Pharm Company Information Table 108. Kingond Pharm Business Overview Table 109. Kingond Pharm Hepatocellular Carcinoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 110. Kingond Pharm Hepatocellular Carcinoma Drug Product Portfolio Table 111. Kingond Pharm Recent Development Table 112. Gilead Sciences Company Information Table 113. Gilead Sciences Business Overview Table 114. Gilead Sciences Hepatocellular Carcinoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 115. Gilead Sciences Hepatocellular Carcinoma Drug Product Portfolio Table 116. Gilead Sciences Recent Development Table 117. Fudan-Zhangjiang Company Information Table 118. Fudan-Zhangjiang Business Overview Table 119. Fudan-Zhangjiang Hepatocellular Carcinoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 120. Fudan-Zhangjiang Hepatocellular Carcinoma Drug Product Portfolio Table 121. Fudan-Zhangjiang Recent Development Table 122. CSPC Company Information Table 123. CSPC Business Overview Table 124. CSPC Hepatocellular Carcinoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 125. CSPC Hepatocellular Carcinoma Drug Product Portfolio Table 126. CSPC Recent Development Table 127. North America Hepatocellular Carcinoma Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 128. North America Hepatocellular Carcinoma Drug Sales by Country (2021-2026) & (k units) Table 129. North America Hepatocellular Carcinoma Drug Sales Market Share by Country (2021-2026) Table 130. North America Hepatocellular Carcinoma Drug Sales Forecast by Country (2027-2032) & (k units) Table 131. North America Hepatocellular Carcinoma Drug Sales Market Share Forecast by Country (2027-2032) Table 132. North America Hepatocellular Carcinoma Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 133. North America Hepatocellular Carcinoma Drug Market Size by Country (2021-2026) & (US$ Million) Table 134. North America Hepatocellular Carcinoma Drug Market Share by Country (2021-2026) Table 135. North America Hepatocellular Carcinoma Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 136. North America Hepatocellular Carcinoma Drug Market Share Forecast by Country (2027-2032) Table 137. Europe Hepatocellular Carcinoma Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 138. Europe Hepatocellular Carcinoma Drug Sales by Country (2021-2026) & (k units) Table 139. Europe Hepatocellular Carcinoma Drug Sales Market Share by Country (2021-2026) Table 140. Europe Hepatocellular Carcinoma Drug Sales Forecast by Country (2027-2032) & (k units) Table 141. Europe Hepatocellular Carcinoma Drug Sales Market Share Forecast by Country (2027-2032) Table 142. Europe Hepatocellular Carcinoma Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 143. Europe Hepatocellular Carcinoma Drug Market Size by Country (2021-2026) & (US$ Million) Table 144. Europe Hepatocellular Carcinoma Drug Market Share by Country (2021-2026) Table 145. Europe Hepatocellular Carcinoma Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 146. Europe Hepatocellular Carcinoma Drug Market Share Forecast by Country (2027-2032) Table 147. Asia-Pacific Hepatocellular Carcinoma Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 148. Asia-Pacific Hepatocellular Carcinoma Drug Sales by Country (2021-2026) & (k units) Table 149. Asia-Pacific Hepatocellular Carcinoma Drug Sales Market Share by Country (2021-2026) Table 150. Asia-Pacific Hepatocellular Carcinoma Drug Sales Forecast by Country (2027-2032) & (k units) Table 151. Asia-Pacific Hepatocellular Carcinoma Drug Sales Market Share Forecast by Country (2027-2032) Table 152. Asia-Pacific Hepatocellular Carcinoma Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 153. Asia-Pacific Hepatocellular Carcinoma Drug Market Size by Country (2021-2026) & (US$ Million) Table 154. Asia-Pacific Hepatocellular Carcinoma Drug Market Share by Country (2021-2026) Table 155. Asia-Pacific Hepatocellular Carcinoma Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 156. Asia-Pacific Hepatocellular Carcinoma Drug Market Share Forecast by Country (2027-2032) Table 157. Latin America Hepatocellular Carcinoma Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 158. Latin America Hepatocellular Carcinoma Drug Sales by Country (2021-2026) & (k units) Table 159. Latin America Hepatocellular Carcinoma Drug Sales Market Share by Country (2021-2026) Table 160. Latin America Hepatocellular Carcinoma Drug Sales Forecast by Country (2027-2032) & (k units) Table 161. Latin America Hepatocellular Carcinoma Drug Sales Market Share Forecast by Country (2027-2032) Table 162. Latin America Hepatocellular Carcinoma Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 163. Latin America Hepatocellular Carcinoma Drug Market Size by Country (2021-2026) & (US$ Million) Table 164. Latin America Hepatocellular Carcinoma Drug Market Share by Country (2021-2026) Table 165. Latin America Hepatocellular Carcinoma Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 166. Latin America Hepatocellular Carcinoma Drug Market Share Forecast by Country (2027-2032) Table 167. Middle East and Africa Hepatocellular Carcinoma Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 168. Middle East and Africa Hepatocellular Carcinoma Drug Sales by Country (2021-2026) & (k units) Table 169. Middle East and Africa Hepatocellular Carcinoma Drug Sales Market Share by Country (2021-2026) Table 170. Middle East and Africa Hepatocellular Carcinoma Drug Sales Forecast by Country (2027-2032) & (k units) Table 171. Middle East and Africa Hepatocellular Carcinoma Drug Sales Market Share Forecast by Country (2027-2032) Table 172. Middle East and Africa Hepatocellular Carcinoma Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 173. Middle East and Africa Hepatocellular Carcinoma Drug Market Size by Country (2021-2026) & (US$ Million) Table 174. Middle East and Africa Hepatocellular Carcinoma Drug Market Share by Country (2021-2026) Table 175. Middle East and Africa Hepatocellular Carcinoma Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 176. Middle East and Africa Hepatocellular Carcinoma Drug Market Share Forecast by Country (2027-2032) Table 177. Key Raw Materials Table 178. Raw Materials Key Suppliers Table 179. Hepatocellular Carcinoma Drug Distributors List Table 180. Hepatocellular Carcinoma Drug Customers List Table 181. Research Programs/Design for This Report Table 182. Authors List of This Report Table 183. Secondary Sources Table 184. Primary Sources List of Figures Figure 1. Hepatocellular Carcinoma Drug Image Figure 2. Global Hepatocellular Carcinoma Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hepatocellular Carcinoma Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Hepatocellular Carcinoma Drug Sales (2021-2032) & (k units) Figure 5. Ablation Therapy Image Figure 6. Global Ablation Therapy Sales YoY Growth (2021-2032) & (k units) Figure 7. Brachytherapy Image Figure 8. Global Brachytherapy Sales YoY Growth (2021-2032) & (k units) Figure 9. Chemotherapy Image Figure 10. Global Chemotherapy Sales YoY Growth (2021-2032) & (k units) Figure 11. Global Hepatocellular Carcinoma Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 12. Global Hepatocellular Carcinoma Drug Market Share by Type 2025 VS 2032 Figure 13. North America Hepatocellular Carcinoma Drug Sales Market Share in Volume by Type in 2025 Figure 14. North America Hepatocellular Carcinoma Drug Sales Market Share in Value by Type in 2025 Figure 15. Europe Hepatocellular Carcinoma Drug Sales Market Share in Volume by Type in 2025 Figure 16. Europe Hepatocellular Carcinoma Drug Sales Market Share in Value by Type in 2025 Figure 17. Asia-Pacific Hepatocellular Carcinoma Drug Sales Market Share in Volume by Type in 2025 Figure 18. Asia-Pacific Hepatocellular Carcinoma Drug Sales Market Share in Value by Type in 2025 Figure 19. Latin America Hepatocellular Carcinoma Drug Sales Market Share in Volume by Type in 2025 Figure 20. Latin America Hepatocellular Carcinoma Drug Sales Market Share in Value by Type in 2025 Figure 21. Middle East and Africa Hepatocellular Carcinoma Drug Sales Market Share in Volume by Type in 2025 Figure 22. Middle East and Africa Hepatocellular Carcinoma Drug Sales Market Share in Value by Type in 2025 Figure 23. Global Top 5 and 10 Hepatocellular Carcinoma Drug Players Market Share by Revenue in 2025 Figure 24. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 25. Surgical Resection Image Figure 26. Global Surgical Resection Sales YoY Growth (2021-2032) & (k units) Figure 27. Ablation Image Figure 28. Global Ablation Sales YoY Growth (2021-2032) & (k units) Figure 29. Liver Transplantation Image Figure 30. Global Liver Transplantation Sales YoY Growth (2021-2032) & (k units) Figure 31. Global Hepatocellular Carcinoma Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 32. Global Hepatocellular Carcinoma Drug Market Share by Application 2025 VS 2032 Figure 33. North America Hepatocellular Carcinoma Drug Sales Market Share in Volume by Application in 2025 Figure 34. North America Hepatocellular Carcinoma Drug Sales Market Share in Value by Application in 2025 Figure 35. Europe Hepatocellular Carcinoma Drug Sales Market Share in Volume by Application in 2025 Figure 36. Europe Hepatocellular Carcinoma Drug Sales Market Share in Value by Application in 2025 Figure 37. Asia-Pacific Hepatocellular Carcinoma Drug Sales Market Share in Volume by Application in 2025 Figure 38. Asia-Pacific Hepatocellular Carcinoma Drug Sales Market Share in Value by Application in 2025 Figure 39. Latin America Hepatocellular Carcinoma Drug Sales Market Share in Volume by Application in 2025 Figure 40. Latin America Hepatocellular Carcinoma Drug Sales Market Share in Value by Application in 2025 Figure 41. Middle East and Africa Hepatocellular Carcinoma Drug Sales Market Share in Volume by Application in 2025 Figure 42. Middle East and Africa Hepatocellular Carcinoma Drug Sales Market Share in Value by Application in 2025 Figure 43. North America Hepatocellular Carcinoma Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 44. North America Hepatocellular Carcinoma Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. North America Hepatocellular Carcinoma Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. North America Hepatocellular Carcinoma Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Hepatocellular Carcinoma Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 48. Europe Hepatocellular Carcinoma Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Hepatocellular Carcinoma Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Europe Hepatocellular Carcinoma Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Hepatocellular Carcinoma Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 52. Asia-Pacific Hepatocellular Carcinoma Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Hepatocellular Carcinoma Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Asia-Pacific Hepatocellular Carcinoma Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Hepatocellular Carcinoma Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 56. Latin America Hepatocellular Carcinoma Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Hepatocellular Carcinoma Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Latin America Hepatocellular Carcinoma Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Hepatocellular Carcinoma Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 60. Middle East and Africa Hepatocellular Carcinoma Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Hepatocellular Carcinoma Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Middle East and Africa Hepatocellular Carcinoma Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Hepatocellular Carcinoma Drug Value Chain Figure 64. Key Raw Materials Price Figure 65. Manufacturing Cost Structure Figure 66. Hepatocellular Carcinoma Drug Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Ablation Therapy
  • Brachytherapy
  • Chemotherapy
Applications
  • Surgical Resection
  • Ablation
  • Liver Transplantation
Companies covered
  • Teva Pharmaceutical
  • Sun Pharmaceutical
  • Johnson & Johnson
  • Novartis
  • Sigma-Tau Group
  • Pacira
  • Luye Pharma
  • Kingond Pharm
  • Gilead Sciences
  • Fudan-Zhangjiang
  • CSPC

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Hepatocellular Carcinoma Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Hepatocellular Carcinoma Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Hepatocellular Carcinoma Drug Market by Type
  6. 1.3.1 Ablation Therapy
  7. 1.3.2 Brachytherapy
  8. 1.3.3 Chemotherapy
  9. 1.4 Global Hepatocellular Carcinoma Drug Market Size by Type
  10. 1.4.1 Global Hepatocellular Carcinoma Drug Market Size Overview by Type (2021-2032)
  11. 1.4.2 Global Hepatocellular Carcinoma Drug Historic Market Size Review by Type (2021-2026)
  12. 1.4.3 Global Hepatocellular Carcinoma Drug Forecasted Market Size by Type (2027-2032)
  13. 1.5 Key Regions Market Size by Type
  14. 1.5.1 North America Hepatocellular Carcinoma Drug Sales Breakdown by Type (2021-2026)
  15. 1.5.2 Europe Hepatocellular Carcinoma Drug Sales Breakdown by Type (2021-2026)
  16. 1.5.3 Asia-Pacific Hepatocellular Carcinoma Drug Sales Breakdown by Type (2021-2026)
  17. 1.5.4 South America Hepatocellular Carcinoma Drug Sales Breakdown by Type (2021-2026)
  18. 1.5.5 Middle East and Africa Hepatocellular Carcinoma Drug Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Hepatocellular Carcinoma Drug Industry Trends
  2. 2.2 Hepatocellular Carcinoma Drug Industry Drivers
  3. 2.3 Hepatocellular Carcinoma Drug Industry Opportunities and Challenges
  4. 2.4 Hepatocellular Carcinoma Drug Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Hepatocellular Carcinoma Drug Revenue (2021-2026)
  2. 3.2 Global Top Players by Hepatocellular Carcinoma Drug Sales (2021-2026)
  3. 3.3 Global Top Players by Hepatocellular Carcinoma Drug Price (2021-2026)
  4. 3.4 Global Hepatocellular Carcinoma Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Hepatocellular Carcinoma Drug Major Company Production Sites & Headquarters
  6. 3.6 Global Hepatocellular Carcinoma Drug Company, Product Type & Application
  7. 3.7 Global Hepatocellular Carcinoma Drug Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Hepatocellular Carcinoma Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Hepatocellular Carcinoma Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Hepatocellular Carcinoma Drug Tier 1, Tier 2, and Tier 3
4 Hepatocellular Carcinoma Drug Regional Status and Outlook
  1. 4.1 Global Hepatocellular Carcinoma Drug Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Hepatocellular Carcinoma Drug Historic Market Size by Region
  3. 4.2.1 Global Hepatocellular Carcinoma Drug Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Hepatocellular Carcinoma Drug Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Hepatocellular Carcinoma Drug Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Hepatocellular Carcinoma Drug Forecasted Market Size by Region
  7. 4.3.1 Global Hepatocellular Carcinoma Drug Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Hepatocellular Carcinoma Drug Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Hepatocellular Carcinoma Drug Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Hepatocellular Carcinoma Drug by Application
  1. 5.1 Hepatocellular Carcinoma Drug Market by Application
  2. 5.1.1 Surgical Resection
  3. 5.1.2 Ablation
  4. 5.1.3 Liver Transplantation
  5. 5.2 Global Hepatocellular Carcinoma Drug Market Size by Application
  6. 5.2.1 Global Hepatocellular Carcinoma Drug Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Hepatocellular Carcinoma Drug Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Hepatocellular Carcinoma Drug Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Hepatocellular Carcinoma Drug Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Hepatocellular Carcinoma Drug Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Hepatocellular Carcinoma Drug Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Hepatocellular Carcinoma Drug Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Hepatocellular Carcinoma Drug Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Teva Pharmaceutical
  2. 6.1.1 Teva Pharmaceutical Company Information
  3. 6.1.2 Teva Pharmaceutical Business Overview
  4. 6.1.3 Teva Pharmaceutical Hepatocellular Carcinoma Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Teva Pharmaceutical Hepatocellular Carcinoma Drug Product Portfolio
  6. 6.1.5 Teva Pharmaceutical Recent Developments
  7. 6.2 Sun Pharmaceutical
  8. 6.2.1 Sun Pharmaceutical Company Information
  9. 6.2.2 Sun Pharmaceutical Business Overview
  10. 6.2.3 Sun Pharmaceutical Hepatocellular Carcinoma Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Sun Pharmaceutical Hepatocellular Carcinoma Drug Product Portfolio
  12. 6.2.5 Sun Pharmaceutical Recent Developments
  13. 6.3 Johnson & Johnson
  14. 6.3.1 Johnson & Johnson Company Information
  15. 6.3.2 Johnson & Johnson Business Overview
  16. 6.3.3 Johnson & Johnson Hepatocellular Carcinoma Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Johnson & Johnson Hepatocellular Carcinoma Drug Product Portfolio
  18. 6.3.5 Johnson & Johnson Recent Developments
  19. 6.4 Novartis
  20. 6.4.1 Novartis Company Information
  21. 6.4.2 Novartis Business Overview
  22. 6.4.3 Novartis Hepatocellular Carcinoma Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Novartis Hepatocellular Carcinoma Drug Product Portfolio
  24. 6.4.5 Novartis Recent Developments
  25. 6.5 Sigma-Tau Group
  26. 6.5.1 Sigma-Tau Group Company Information
  27. 6.5.2 Sigma-Tau Group Business Overview
  28. 6.5.3 Sigma-Tau Group Hepatocellular Carcinoma Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Sigma-Tau Group Hepatocellular Carcinoma Drug Product Portfolio
  30. 6.5.5 Sigma-Tau Group Recent Developments
  31. 6.6 Pacira
  32. 6.6.1 Pacira Company Information
  33. 6.6.2 Pacira Business Overview
  34. 6.6.3 Pacira Hepatocellular Carcinoma Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Pacira Hepatocellular Carcinoma Drug Product Portfolio
  36. 6.6.5 Pacira Recent Developments
  37. 6.7 Luye Pharma
  38. 6.7.1 Luye Pharma Company Information
  39. 6.7.2 Luye Pharma Business Overview
  40. 6.7.3 Luye Pharma Hepatocellular Carcinoma Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Luye Pharma Hepatocellular Carcinoma Drug Product Portfolio
  42. 6.7.5 Luye Pharma Recent Developments
  43. 6.8 Kingond Pharm
  44. 6.8.1 Kingond Pharm Company Information
  45. 6.8.2 Kingond Pharm Business Overview
  46. 6.8.3 Kingond Pharm Hepatocellular Carcinoma Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Kingond Pharm Hepatocellular Carcinoma Drug Product Portfolio
  48. 6.8.5 Kingond Pharm Recent Developments
  49. 6.9 Gilead Sciences
  50. 6.9.1 Gilead Sciences Company Information
  51. 6.9.2 Gilead Sciences Business Overview
  52. 6.9.3 Gilead Sciences Hepatocellular Carcinoma Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Gilead Sciences Hepatocellular Carcinoma Drug Product Portfolio
  54. 6.9.5 Gilead Sciences Recent Developments
  55. 6.10 Fudan-Zhangjiang
  56. 6.10.1 Fudan-Zhangjiang Company Information
  57. 6.10.2 Fudan-Zhangjiang Business Overview
  58. 6.10.3 Fudan-Zhangjiang Hepatocellular Carcinoma Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Fudan-Zhangjiang Hepatocellular Carcinoma Drug Product Portfolio
  60. 6.10.5 Fudan-Zhangjiang Recent Developments
  61. 6.11 CSPC
  62. 6.11.1 CSPC Company Information
  63. 6.11.2 CSPC Business Overview
  64. 6.11.3 CSPC Hepatocellular Carcinoma Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 CSPC Hepatocellular Carcinoma Drug Product Portfolio
  66. 6.11.5 CSPC Recent Developments
7 North America by Country
  1. 7.1 North America Hepatocellular Carcinoma Drug Sales by Country
  2. 7.1.1 North America Hepatocellular Carcinoma Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Hepatocellular Carcinoma Drug Sales by Country (2021-2026)
  4. 7.1.3 North America Hepatocellular Carcinoma Drug Sales Forecast by Country (2027-2032)
  5. 7.2 North America Hepatocellular Carcinoma Drug Market Size by Country
  6. 7.2.1 North America Hepatocellular Carcinoma Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Hepatocellular Carcinoma Drug Market Size by Country (2021-2026)
  8. 7.2.3 North America Hepatocellular Carcinoma Drug Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Hepatocellular Carcinoma Drug Sales by Country
  2. 8.1.1 Europe Hepatocellular Carcinoma Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Hepatocellular Carcinoma Drug Sales by Country (2021-2026)
  4. 8.1.3 Europe Hepatocellular Carcinoma Drug Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Hepatocellular Carcinoma Drug Market Size by Country
  6. 8.2.1 Europe Hepatocellular Carcinoma Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Hepatocellular Carcinoma Drug Market Size by Country (2021-2026)
  8. 8.2.3 Europe Hepatocellular Carcinoma Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Hepatocellular Carcinoma Drug Sales by Country
  2. 9.1.1 Asia-Pacific Hepatocellular Carcinoma Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Hepatocellular Carcinoma Drug Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Hepatocellular Carcinoma Drug Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Hepatocellular Carcinoma Drug Market Size by Country
  6. 9.2.1 Asia-Pacific Hepatocellular Carcinoma Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Hepatocellular Carcinoma Drug Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Hepatocellular Carcinoma Drug Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Hepatocellular Carcinoma Drug Sales by Country
  2. 10.1.1 South America Hepatocellular Carcinoma Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Hepatocellular Carcinoma Drug Sales by Country (2021-2026)
  4. 10.1.3 South America Hepatocellular Carcinoma Drug Sales Forecast by Country (2027-2032)
  5. 10.2 South America Hepatocellular Carcinoma Drug Market Size by Country
  6. 10.2.1 South America Hepatocellular Carcinoma Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Hepatocellular Carcinoma Drug Market Size by Country (2021-2026)
  8. 10.2.3 South America Hepatocellular Carcinoma Drug Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Hepatocellular Carcinoma Drug Sales by Country
  2. 11.1.1 Middle East and Africa Hepatocellular Carcinoma Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Hepatocellular Carcinoma Drug Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Hepatocellular Carcinoma Drug Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Hepatocellular Carcinoma Drug Market Size by Country
  6. 11.2.1 Middle East and Africa Hepatocellular Carcinoma Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Hepatocellular Carcinoma Drug Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Hepatocellular Carcinoma Drug Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Hepatocellular Carcinoma Drug Value Chain Analysis
  2. 12.1.1 Hepatocellular Carcinoma Drug Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Hepatocellular Carcinoma Drug Production Mode & Process
  7. 12.2 Hepatocellular Carcinoma Drug Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Hepatocellular Carcinoma Drug Distributors
  10. 12.2.3 Hepatocellular Carcinoma Drug Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst